Patient Monitoring during Treatment with Ocrelizumab and Rituximab (ORP-49)
Monoclonal antibodies that target CD20 expressing B cells represent an important new treatment option for patients with multiple sclerosis (MS). This therapy may be associated with an increased risk of adverse effects which are reviewed in this study. The generally favorable safety profile of anti-...
Main Author: | Nazanin Razazian |
---|---|
Format: | Article |
Language: | English |
Published: |
Iran University of Medical Sciences
2023-01-01
|
Series: | Neurology Letters |
Subjects: | |
Online Access: | https://www.neurologyletters.com/article_184690_d41d8cd98f00b204e9800998ecf8427e.pdf |
Similar Items
-
NK Cell Levels Correlate with Disease Activity in Patients with Multiple Sclerosis on Ocrelizumab/Rituximab Therapy
by: Simone Dal Bello, et al.
Published: (2024-01-01) -
Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
by: Mansour A. Alharbi, et al.
Published: (2023-05-01) -
OCRELIZUMAB IN THE TREATMENT OF PRIMARY-PROGRESSIVE MULTIPLE SCLEROSIS
by: E. V. Popova
Published: (2018-02-01) -
Alopecia universalis in a patient under treatment of Ocrelizumab after switching from Rituximab (PP-06)
by: Mahshid Mahyad, et al.
Published: (2023-01-01) -
The Effect of Ocrelizumab in the Treatment of Multipl Sclerosis
by: Şenay Yıldız Çelik
Published: (2017-09-01)